QRG Capital Management Inc. Acquires 3,133 Shares of Thermo Fisher Scientific Inc. $TMO

QRG Capital Management Inc. boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 14.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 24,729 shares of the medical research company’s stock after acquiring an additional 3,133 shares during the period. QRG Capital Management Inc.’s holdings in Thermo Fisher Scientific were worth $12,155,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in TMO. Vanguard Group Inc. boosted its stake in shares of Thermo Fisher Scientific by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company’s stock valued at $19,778,774,000 after purchasing an additional 288,296 shares in the last quarter. J. Stern & Co. LLP raised its stake in Thermo Fisher Scientific by 58,006.4% in the fourth quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock worth $18,258,082,000 after buying an additional 31,455,105 shares in the last quarter. State Street Corp lifted its holdings in Thermo Fisher Scientific by 1.4% in the fourth quarter. State Street Corp now owns 16,613,761 shares of the medical research company’s stock worth $9,633,991,000 after buying an additional 229,630 shares during the period. Capital World Investors boosted its position in Thermo Fisher Scientific by 7.0% during the 4th quarter. Capital World Investors now owns 11,003,814 shares of the medical research company’s stock valued at $6,376,229,000 after acquiring an additional 718,669 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Thermo Fisher Scientific by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 8,196,477 shares of the medical research company’s stock worth $4,728,129,000 after acquiring an additional 26,425 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Sanford C. Bernstein assumed coverage on Thermo Fisher Scientific in a research report on Friday, June 26th. They set a “market perform” rating and a $520.00 price target on the stock. Weiss Ratings downgraded Thermo Fisher Scientific from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, June 29th. Jefferies Financial Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a report on Friday, April 24th. Stifel Nicolaus reduced their target price on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a research report on Friday, April 24th. Finally, DZ Bank assumed coverage on shares of Thermo Fisher Scientific in a research report on Friday, March 27th. They set a “buy” rating and a $610.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $605.09.

Insider Transactions at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the transaction, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.2%

TMO stock opened at $522.38 on Friday. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. The business has a 50 day moving average of $473.17 and a 200 day moving average of $518.15. Thermo Fisher Scientific Inc. has a twelve month low of $403.36 and a twelve month high of $643.99. The firm has a market cap of $194.13 billion, a PE ratio of 28.72, a price-to-earnings-growth ratio of 2.32 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm had revenue of $11.01 billion for the quarter, compared to analysts’ expectations of $10.86 billion. During the same period in the prior year, the firm posted $5.15 earnings per share. The company’s quarterly revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 24.84 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Monday, June 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.34%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.